Power3 Secures Rights to Test for Breast Cancer

Under a new agreement, exclusive rights to the patents and technologies developed in collaboration with the University of Texas (UT) M.D. Anderson Cancer Center (Houston, USA) for an early breast cancer test have been secured by Power3 Medical Products, Inc. (The Woodlands, TX, USA).

The agreement provides for the detection, diagnosis, and monitoring of breast cancer through proteomic analysis of nipple aspirate fluids (NAF). The fluid obtained through a noninvasive procedure utilizing a modified breast pump is collected from the breast ductal region where most breast cancers originate. When analyzed by Power3 Products' patent pending methodology and technology, the proteins in this fluid reveal specific disease protein footprints. The technology resulted from the joint development efforts of Power3 Products Medical and UT M.D. Anderson, including joint filings and publications.

"We have identified 130 protein biomarkers that we believe not only provide for the early detection of breast cancer but reveal the blueprint for how cancer develops,” commented Ira L. Goldknopf, Ph.D., chief scientific officer of Power3 Medical. "The technology holds great promise for commercialization in large markets with the potential to achieve an earlier and more accurate diagnosis of breast cancer and ultimately identify specific drug targets for earlier treatment.”

Power3 Medical is engaged in the discovery of protein footprints, pathways, and mechanisms of disease that the company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease.





Related Links:
UT M.D. Anderson Cancer Center
Power3 Medical Products